Trial · NCT04987489
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohorts A: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Primary | Cohorts B: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Primary | Cohort C: Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline) | 12 weeks | Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline) |
| Secondary | Cohort A: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Secondary | Cohort B: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 12 weeks | 12 weeks | Reduction in red blood cell transfusions over 12 weeks |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 24 weeks | 24 weeks | Reduction in red blood cell transfusions over 24 weeks |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 48 weeks | 48 weeks | Reduction in red blood cell transfusions over 48 weeks |
| Secondary | Cohort B: Reduction in red blood cell transfusions over 12 weeks | 12 weeks | Reduction in red blood cell transfusions over 12 weeks |
| Secondary | Cohort B: Reduction in red blood cell transfusions over 24 weeks | 24 weeks | Reduction in red blood cell transfusions over 24 weeks |
| Secondary | Cohort B: Reduction in red blood cell transfusions over 48 weeks | 48 weeks | Reduction in red blood cell transfusions over 48 weeks |
| Secondary | Cohort C: Hemoglobin response rate at Week 24 (increase of ≥ 1.0 g/dL from baseline). | 24 weeks | Hemoglobin response rate at Week 24 (increase of ≥ 1.0 g/dL from baseline). |
| Secondary | Cohort C: Hemoglobin response rate at Week 48 (increase of ≥ 1.0 g/dL from baseline). | 48 weeks | Hemoglobin response rate at Week 48 (increase of ≥ 1.0 g/dL from baseline). |
| Secondary | Change from baseline in hemoglobin over 12 weeks | 12 weeks | Change from baseline in hemoglobin over 12 weeks |
| Secondary | Change from baseline in hemoglobin over 24 weeks | 24 weeks | Change from baseline in hemoglobin over 24 weeks |
| Secondary | Change from baseline in hemoglobin over 48 weeks | 48 weeks | Change from baseline in hemoglobin over 48 weeks |
| Secondary | Changes in serum ferritin levels at 12 weeks versus baseline | 12 weeks | Changes in serum ferritin levels at 12 weeks versus baseline |
| Secondary | Changes in serum ferritin levels at 24 weeks versus baseline | 24 weeks | Changes in serum ferritin levels at 24 weeks versus baseline |
| Secondary | Changes in serum ferritin levels at 48 weeks versus baseline | 48 weeks | Changes in serum ferritin levels at 48 weeks versus baseline |
| Secondary | Changes in liver iron concentration at 48 weeks versus baseline | 48 weeks | Changes in liver iron concentration at 48 weeks versus baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04987489/registered